Our group previously found that delivery of IL‐24 via a CRAd (ZD55‐IL‐24), in combination withdacarbazine, has a greater antitumor effect in melanoma cells than either of these agents when used alone.30 ZD55‐IL‐24 attaches to tumor cells using CAR; however, the expression of CAR in most types of cancer cells is low or absent.20 Therefore, IL‐24 expression levels following ZD55‐IL‐24 infection of cancer tumor cells are still insufficient. The gene discussed is IL24; the disease is melanoma.